BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20699094)

  • 1. Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ.
    Krüger S; Ewig S; Kunde J; Hartmann O; Marre R; Suttorp N; Welte T;
    Clin Chim Acta; 2010 Dec; 411(23-24):1929-34. PubMed ID: 20699094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.
    Krüger S; Ewig S; Papassotiriou J; Kunde J; Marre R; von Baum H; Suttor N; Welte T;
    Respir Res; 2009 Jul; 10(1):65. PubMed ID: 19594893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
    Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
    Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
    Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
    Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
    Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia.
    Lee JY; Hwang SJ; Shim JW; Jung HL; Park MS; Woo HY; Shim JY
    Korean J Lab Med; 2010 Aug; 30(4):406-13. PubMed ID: 20805714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of serum procalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosis.
    Niu WY; Wan YG; Li MY; Wu ZX; Zhang LG; Wang JX
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3329-33. PubMed ID: 24379064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procalcitonin kinetics in Legionella pneumophila pneumonia.
    de Jager CP; de Wit NC; Weers-Pothoff G; van der Poll T; Wever PC
    Clin Microbiol Infect; 2009 Nov; 15(11):1020-5. PubMed ID: 19438643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
    Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia.
    Guo S; Mao X; Liang M
    Respir Res; 2018 Oct; 19(1):193. PubMed ID: 30285748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis.
    Hoshina T; Nanishi E; Kanno S; Nishio H; Kusuhara K; Hara T
    J Infect Chemother; 2014 Oct; 20(10):616-20. PubMed ID: 25027057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia.
    Perren A; Cerutti B; Lepori M; Senn V; Capelli B; Duchini F; Domenighetti G
    Infection; 2008 Mar; 36(2):163-6. PubMed ID: 18330505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biomarkers in community acquired pneumonia - what did we learn from the CAPNETZ study?].
    Krüger S; Pletz MW; Rohde G
    Pneumologie; 2011 Feb; 65(2):110-3. PubMed ID: 21117019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children.
    Agnello L; Bellia C; Di Gangi M; Lo Sasso B; Calvaruso L; Bivona G; Scazzone C; Dones P; Ciaccio M
    Clin Biochem; 2016 Jan; 49(1-2):47-50. PubMed ID: 26386341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of procalcitonin for differentiating cryptogenic organising pneumonia from community-acquired pneumonia.
    Ito A; Ishida T; Tachibana H; Arita M; Yamazaki A; Washio Y
    Clin Chem Lab Med; 2019 Sep; 57(10):1632-1637. PubMed ID: 31120857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of serum procalcitonin in differential diagnosis of pulmonary embolism and community-acquired pneumonia.
    Köktürk N; Kanbay A; Bukan N; Ekim N
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):519-25. PubMed ID: 20699253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal community-acquired pneumonia in children.
    Galetto-Lacour A; Alcoba G; Posfay-Barbe KM; Cevey-Macherel M; Gehri M; Ochs MM; Brookes RH; Siegrist CA; Gervaix A
    Pediatr Infect Dis J; 2013 Nov; 32(11):1175-9. PubMed ID: 23694836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.
    Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T
    Respirology; 2016 Nov; 21(8):1459-1464. PubMed ID: 27398948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ.
    Krüger S; Papassotiriou J; Marre R; Richter K; Schumann C; von Baum H; Morgenthaler NG; Suttorp N; Welte T;
    Intensive Care Med; 2007 Dec; 33(12):2069-78. PubMed ID: 17938883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.